Efficacy of Weekly Split versus Single Doses of Ergocalciferol on Serum 25-Hydroxyvitamin D among Patients on Continuous Ambulatory Peritoneal Dialysis: A Randomized Controlled Trial
Table 1
Baseline characteristics.
Characteristics
Total (N = 50)
Ergocalciferol split dose (N = 25)
Ergocalciferol single dose (N = 25)
value
Male (N, %)
23 (46)
13 (52.0)
10 (40.0)
0.395
Age (years)
62.4 ± 15.3
61.1 ± 16.3
63.8 ± 14.6
0.541
Body mass index (kg/m2)
23.3 ± 4.7
22.8 ± 4.8
23.8 ± 4.7
0.453
Hypertension
50 (100)
25 (100)
25 (100)
0.999
Diabetes mellitus
11 (22)
2 (8.0)
9 (36.0)
0.017
Dyslipidemia
15 (30)
5 (20.0)
10 (40.0)
0.123
Time of initiate CAPD (years)
1.3 ± 1.8
1.2 ± 1.6
1.5 ± 2.1
0.646
History infected CAPD
7 (14)
2 (8.0)
5 (20.0)
0.417
25(OH)D ≤ 20 ng/mL (N, %)
18 (36.0)
9 (36.0)
9 (36.0)
0.999
25(OH)D 21–30 ng/mL (N, %)
32 (64.0)
16 (64.0)
16 (64.0)
0.999
Serum 25(OH)D (ng/mL)
22.8 ± 5.5
22.7 ± 5.9
22.9 ± 5.3
0.977
Serum calcium (mg/mL)
9.1 ± 0.6
9.2 ± 0.7
9.1 ± 0.53
0.457
Serum phosphate (mg/mL)
4.5 ± 1.3
4.7 ± 1.4
4.30 ± 1.17
0.266
Intact parathyroid hormone (pg/mL)
263.4 ± 217.1
266.7 ± 255.6
270.0 ± 188.1
0.522
Data in the table are shown with average ± standard deviation and percentages. CAPD, continuous ambulatory peritoneal dialysis; 25(OH)D, 25-hydroxyvitamin D.
